Meyeon Park1, Eric Vittinghoff, Peter Ganz, Carmen A Peralta, Mary Whooley, Michael G Shlipak. 1. From the Division of Nephrology (M.P., C.A.P.), and Departments of Epidemiology and Biostatistics (E.V., M.W., M.G.S.) and Medicine (P.G., M.W., M.G.S.), University of California, San Francisco, CA; Division of Cardiology, San Francisco General Hospital, San Francisco, CA (P.G.); and San Francisco VA Medical Center, San Francisco, CA (M.W., M.G.S.).
Abstract
OBJECTIVE: Endothelial dysfunction is a possible mechanism to explain the association between atherosclerosis and kidney disease. This study evaluated circulating soluble endothelial cell-selective adhesion molecule (sESAM), a marker of endothelial dysfunction, as a risk factor for kidney function decline and albuminuria. APPROACH AND RESULTS: In the Heart and Soul Study, we measured sESAM from baseline serum samples and defined elevated levels of sESAM by the highest quartile (quartile 4 [Q4]: >65.4 ng/mL). We evaluated the associations of high sESAM with baseline estimated glomerular filtration rate (eGFR) and ratio of urine albumin to creatinine (ACR), and with longitudinal changes in eGFR and ACR. Among 990 participants with sESAM measurements, median sESAM was 54.5 ng/mL (interquartile range, 45.3-65.8). After multivariable adjustment, elevated levels of sESAM were strongly and independently associated with baseline reduced eGFR <60 mL/min per 1.73 m(2) (odds ratio [OR], 11.44; P<0.0001) and ACR ≥30 mg/g (OR, 5.23; P<0.0001). Associations of sESAM (Q4 versus quartile 1 [Q1]) with change in ACR (β=54.47; P<0.0001) were also significant after full adjustment. The association with change in eGFR (1.56%; P=0.0049) was not statistically significant after application of the Bonferroni correction for multiple markers. In unadjusted models, sESAM was associated with rapid kidney function loss, defined as 3% annual eGFR decline (OR, 2.28; P=0.0003), although this was attenuated by adjustment (OR, 2.11; P=0.0095). CONCLUSIONS: sESAM is associated with albuminuria and reduced kidney function in both cross-sectional and longitudinal analyses. These findings implicate endothelial dysfunction as a potential contributor to the elevated kidney disease risk in persons with cardiovascular disease.
OBJECTIVE: Endothelial dysfunction is a possible mechanism to explain the association between atherosclerosis and kidney disease. This study evaluated circulating soluble endothelial cell-selective adhesion molecule (sESAM), a marker of endothelial dysfunction, as a risk factor for kidney function decline and albuminuria. APPROACH AND RESULTS: In the Heart and Soul Study, we measured sESAM from baseline serum samples and defined elevated levels of sESAM by the highest quartile (quartile 4 [Q4]: >65.4 ng/mL). We evaluated the associations of high sESAM with baseline estimated glomerular filtration rate (eGFR) and ratio of urine albumin to creatinine (ACR), and with longitudinal changes in eGFR and ACR. Among 990 participants with sESAM measurements, median sESAM was 54.5 ng/mL (interquartile range, 45.3-65.8). After multivariable adjustment, elevated levels of sESAM were strongly and independently associated with baseline reduced eGFR <60 mL/min per 1.73 m(2) (odds ratio [OR], 11.44; P<0.0001) and ACR ≥30 mg/g (OR, 5.23; P<0.0001). Associations of sESAM (Q4 versus quartile 1 [Q1]) with change in ACR (β=54.47; P<0.0001) were also significant after full adjustment. The association with change in eGFR (1.56%; P=0.0049) was not statistically significant after application of the Bonferroni correction for multiple markers. In unadjusted models, sESAM was associated with rapid kidney function loss, defined as 3% annual eGFR decline (OR, 2.28; P=0.0003), although this was attenuated by adjustment (OR, 2.11; P=0.0095). CONCLUSIONS:sESAM is associated with albuminuria and reduced kidney function in both cross-sectional and longitudinal analyses. These findings implicate endothelial dysfunction as a potential contributor to the elevated kidney disease risk in persons with cardiovascular disease.
Authors: T J Anderson; M D Gerhard; I T Meredith; F Charbonneau; D Delagrange; M A Creager; A P Selwyn; P Ganz Journal: Am J Cardiol Date: 1995-02-23 Impact factor: 2.778
Authors: Markus Juonala; Jorma S A Viikari; Tomi Laitinen; Jukka Marniemi; Hans Helenius; Tapani Rönnemaa; Olli T Raitakari Journal: Circulation Date: 2004-10-25 Impact factor: 29.690
Authors: Frank Stam; Coen van Guldener; Annemarie Becker; Jacqueline M Dekker; Robert J Heine; Lex M Bouter; Coen D A Stehouwer Journal: J Am Soc Nephrol Date: 2005-12-28 Impact factor: 10.121
Authors: Mark J Sarnak; Andrew S Levey; Anton C Schoolwerth; Josef Coresh; Bruce Culleton; L Lee Hamm; Peter A McCullough; Bertram L Kasiske; Ellie Kelepouris; Michael J Klag; Patrick Parfrey; Marc Pfeffer; Leopoldo Raij; David J Spinosa; Peter W Wilson Journal: Hypertension Date: 2003-11 Impact factor: 10.190
Authors: Susan Veissi; Bart Smeets; Lambertus P van den Heuvel; Michiel F Schreuder; Jitske Jansen Journal: Pediatr Nephrol Date: 2019-02-28 Impact factor: 3.714